| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 02/19/2004 | WO2004014903A1 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors |
| 02/19/2004 | WO2004014902A2 Compounds having an activity at metabotropic glutamate receptors |
| 02/19/2004 | WO2004014895A1 Piperazine substituted aryl benzodiazepines |
| 02/19/2004 | WO2004014881A2 '1,2,4'oxadiazoles as modulators of metabotropic glutamate receptor-5 |
| 02/19/2004 | WO2004014880A1 Chromone derivatives as matrix metalloproteinase inhibitors |
| 02/19/2004 | WO2004014873A1 4-substituted quinazoline-8-carboxyamide derivative and pharmaceutically acceptable addition salt thereof |
| 02/19/2004 | WO2004014864A1 1h-indazole-3-carboxamide compounds as cyclin dependent kinases (cdk) inhibitors |
| 02/19/2004 | WO2004014861A1 4-substituted-quinoline-8-carboxylic amide derivatives and pharmacologically acceptable addition salts thereof |
| 02/19/2004 | WO2004014859A2 Process for preparing quinolin antibiotic intermediates |
| 02/19/2004 | WO2004014856A1 2,3-dihydro-isoindol-1-ones with mao-b inhibiting activity |
| 02/19/2004 | WO2004014855A1 Processes and polymorphs of diaryl-indolone galr3 antagonists |
| 02/19/2004 | WO2004014850A2 Substituted aminopyrimidines as neurokinin antagonists |
| 02/19/2004 | WO2004014846A1 Modafinil polymorphic forms |
| 02/19/2004 | WO2004014843A1 Substituted amino compounds and use thereof |
| 02/19/2004 | WO2004014825A1 Cannabinoid receptor ligands |
| 02/19/2004 | WO2004014430A1 Compositions of a cyclooxygenase-2 selective inhibitor and a carbonic anhydrase inhibitor for the treatment of neoplasia |
| 02/19/2004 | WO2004014429A1 Regulator for mental disease risk fragility |
| 02/19/2004 | WO2004014425A1 Activators of small conductance calcium activated potassium channels and use thereof |
| 02/19/2004 | WO2004014414A1 Novel uses of rfrp and ot7t022 |
| 02/19/2004 | WO2004014410A1 Composition comprising the extract of cistanche deserticola y.c. ma showing enhancing activity of the neurite outgrowth and neurotrophic effects |
| 02/19/2004 | WO2004014395A1 Female hormone-containing patch |
| 02/19/2004 | WO2004014374A1 Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| 02/19/2004 | WO2004014372A1 Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals |
| 02/19/2004 | WO2004014370A2 Oxadiazoles as modulators of metabotropic glutamate receptor-5 |
| 02/19/2004 | WO2004014369A1 Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals |
| 02/19/2004 | WO2004014367A2 Use of an amyloid beta vaccination in combination with a selective cox-2 inhibitor for the treatment of alzheimer's disease |
| 02/19/2004 | WO2004014357A2 Therapeutic use of aryl amino acid derivatives |
| 02/19/2004 | WO2004014352A2 Methods for treating carbonic anhydrase mediated disorders |
| 02/19/2004 | WO2004014316A2 Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases |
| 02/19/2004 | WO2004014306A2 Compositions and methods for the treatment of diseases exhibiting protein misassembly and aggregation |
| 02/19/2004 | WO2004014304A2 Electrospun amorphous pharmaceutical compositions |
| 02/19/2004 | WO2004014300A2 Tyrosine kinase inhibitors |
| 02/19/2004 | WO2004007478A3 Derivatives of 3-guanidinocarbonyl-1-heteroaryl-pyrrole, process for their preparation and their pharmaceutical use |
| 02/19/2004 | WO2004007430A3 Benzamide or phenylacetamide derivatives useful as thyroid receptor ligands |
| 02/19/2004 | WO2004006886A3 Injectable depot formulation comprising crystals of iloperidone |
| 02/19/2004 | WO2004002463A3 Method of promoting smoking cessation |
| 02/19/2004 | WO2004000840A3 Quinuclidine derivatives and pharmaceutical compositions containing the same |
| 02/19/2004 | WO2004000312A3 Medicament for the treatment of diseases requiring inhibition or a reduction in the activity of ph value-regulating bicarbonate transporter proteins |
| 02/19/2004 | WO2003086306A3 5ht2c receptor modulators |
| 02/19/2004 | WO2003082190A3 Spirocyclic amides as cannabinoid receptor modulators |
| 02/19/2004 | WO2003078658A3 Methods for diagnosing and treating schizophrenia |
| 02/19/2004 | WO2003075850A9 Methods for alzheimer's disease treatment and cognitive enhancement |
| 02/19/2004 | WO2003070188A3 Method of treating trx mediated diseases |
| 02/19/2004 | WO2003065989A3 (oxime)carbamoyl fatty acid amide hydrolase inhibitors |
| 02/19/2004 | WO2003065987A3 Granzyme b inhibitors |
| 02/19/2004 | WO2003065046A3 Diagnostics and therapeutics for diseases associated with a new human 5-ht6 receptor |
| 02/19/2004 | WO2003053136A3 Triple transgenic mouse model of alzheimer's disease |
| 02/19/2004 | WO2003048384A3 Methods of identifying genetic risk for and evaluating treatment of alzheimer's disease by determing single nucleotide polymorphisms |
| 02/19/2004 | WO2003046564A3 Protein biopolymer markers predictive of alzheimers disease |
| 02/19/2004 | WO2003045974A3 Methods and compositions for derepression of iap-inhibited caspase |
| 02/19/2004 | WO2003043639A3 PHARMACEUTICAL COMPOSITION COMPRISING A ClC-2 CHANNEL OPENER |
| 02/19/2004 | WO2003027234A9 Small organic molecule regulators of cell proliferation |
| 02/19/2004 | WO2003025014A3 Use of peptides comprising post-translational modifications in the treatment of autoimmune pathologies |
| 02/19/2004 | WO2003020212A3 Treatment for central nervous system disorders |
| 02/19/2004 | WO2003014731A3 The natural ligand for orphan g protein coupled receptor gpr86 and methods of use |
| 02/19/2004 | WO2002087512A3 Once-a-day oxycodone formulations |
| 02/19/2004 | WO2002065985A3 Methods of treating diabetes mellitus |
| 02/19/2004 | WO2002048337A3 Secreted human proteins |
| 02/19/2004 | WO2002046477A3 Endogenous retroviruses up-regulated in prostate cancer |
| 02/19/2004 | US20040034246 Radiofluorinated imaging agents which are utilzed in Positron Emission Tomography for diagonsis of Parkinson's disease |
| 02/19/2004 | US20040034229 3,4-Di-substituted maleimide compounds as CXC chemokine receptor antagonists |
| 02/19/2004 | US20040034219 Benzothiophene derivative compounds process of preparation and use thereof |
| 02/19/2004 | US20040034218 Farnesyl transferase inhibiting benzoheterocyclic derivatives |
| 02/19/2004 | US20040034104 2,2-Diphenylbutanamide derivatives and medicines containing the same |
| 02/19/2004 | US20040034103 Cdc25 photophatase inhibitors |
| 02/19/2004 | US20040034096 3-Phenyl-propionamido, 3-phenyl-acrylamido and 3-phenyl-propynamido derivatives |
| 02/19/2004 | US20040034093 Methods for enhancing motor performance and/or endurance |
| 02/19/2004 | US20040034092 Such as 5,7,2-trihydroxy-6,8-dimethoxyflavone; plant extracts; side effect reduction; anxiolytic agents |
| 02/19/2004 | US20040034090 Such as (7-chloro-2-methyl-1-(3-(methylsulphanyl)propyl)-1H-indol-3-yl)(2,3-dichloro-phenyl)methanone; cannabinoid receptors (cb2); G proteins coupled receptors |
| 02/19/2004 | US20040034089 Such as (1-((2,3-dihydro-2-(4-propyl-1H-imidazol-2-yl)-1H-indol-1 -yl)carbonyl)propyl)-carbamate; for inactivation of cholecystokinins |
| 02/19/2004 | US20040034083 Combination therapy for the treatment of Parkinson's disease with cyclooxygenase-2 (COX2) inhibitor(s) |
| 02/19/2004 | US20040034081 Estrogen receptor modulators |
| 02/19/2004 | US20040034078 Such as 2-(2-butylamino-ethylsulfanylmethyl)-1H-benzimidazole-4-carboxylic acid amide for treatment of cancer, strokes, head trauma, and neurodengenerative diseases; solid phase synthesis |
| 02/19/2004 | US20040034073 Analgesic agents, modulating the activity of a cannabinoid receptor, treating hypertension, inflammation, pain, autoimmune diseases, allergic diseases, glaucoma, multiple sclerosis, Huntington's chorea, spinal chord injury |
| 02/19/2004 | US20040034070 Propanolaminotetralines, preparation thereof and compositions containing same |
| 02/19/2004 | US20040034069 Nitrogen-containing compounds and their use as glycine transport inhibitors |
| 02/19/2004 | US20040034066 Rosiglitazone hydrochloride is stable, water solubility, high melting point, bulk flow and good for bulk preparation and handling; salt formation |
| 02/19/2004 | US20040034065 A mixture of valsartan, an insulin secretion enhancer or a insulin sensitizer, for treating hypertension, congestive heart failure, diabetes, type 2 diabetes, renal failure, premenstrual syndrome, coronary heart disease |
| 02/19/2004 | US20040034061 An antagonist of corticotropin releasing factor receptor, treating depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastrointestinal disorders, drug dependence |
| 02/19/2004 | US20040034059 A dosage concentration about 0.4 to 75 mg/mL of fentanyl in water, for the pain treatment |
| 02/19/2004 | US20040034057 Salt formation by dissolving donepezil in ethanol, adding hydrogen chloride, forming polymorphic crystal |
| 02/19/2004 | US20040034055 For treating central nervous system disorders, immunomodulatory disorders, antimalaria, viral disease of Borna virus, Hepatitis; a 6-azatricyclo(6.3.1.01,6)dodecane derivatives |
| 02/19/2004 | US20040034049 A benzofuran derivatives for treating neurodegenerative disease, such as Alzheimer's disease, Parkinson's disease, amyotropic lateral sclerosis and Huntington's disease |
| 02/19/2004 | US20040034046 Quinazoline derivatives |
| 02/19/2004 | US20040034044 Quinazoline derivatives and drugs |
| 02/19/2004 | US20040034043 Positively-charged peptide nucleic acid analogs with improved properties |
| 02/19/2004 | US20040034037 Heteroaryl compounds useful as inhibitors of GSK-3 |
| 02/19/2004 | US20040034036 A serotonin 6 (5-HT6) receptor antagonist useful in the treatment of CNS disorders; oral bioavailability; Alzheimers disease; cognitive activators; attention deficit disorder; antidepressants; anxiolytic agents; headaches; hyperactivity |
| 02/19/2004 | US20040034035 Calcium channel inhibitors comprising benzhydril spaced from piperazine |
| 02/19/2004 | US20040034031 3,4-Disubstituted, 3,5-disubstituted and 3,4,5-substituted piperidines |
| 02/19/2004 | US20040034029 Composition and method for altering levels of or sensitivity to adenosine with a dehydroepiandrosterone |
| 02/19/2004 | US20040034026 The use of a vasculostatic compound and a second active ingredient which decreases the activity of the epidermal growth factor (EGF); synergistic, angiogenesis inhibitors; antiproliferative agents; tyrosine kinase enzyme inhibitors |
| 02/19/2004 | US20040034017 4-fluoroalkyl-2h-benzopyrans anti-estogenic activity |
| 02/19/2004 | US20040034015 Administering to a human patient suffering from addictive behavior associated with 5HT2C receptor modulation, a fused tetra or pentaheterocyclic compound containing nitrogen in the rings |
| 02/19/2004 | US20040034011 Administering to a mammal a napthalene derivative containing at least two hydroxy groups at ortho position to one another, for the treatment of disorders caused by catechol-O-methyltransferase enzyme |
| 02/19/2004 | US20040034010 Administering an effective amount of quetiapine or a salt to a patient having attention deficit hyperactivity disorder or conduct disorder |
| 02/19/2004 | US20040034005 Administering to a patient suffering from psychological disoders a (1,4)diazocino(7,7,1-hi)inodle derivative as 5HT2c agonist or partial agonist |
| 02/19/2004 | US20040034002 3Alpha-hydroxy-3beta-methoxymethyl-substituted steroids and the use thereof |
| 02/19/2004 | US20040033995 Nitrogen compounds, stereoisomers and/or racemic mixtures used as enzyme inhibitors for prophylaxis of inflammatory diseases |
| 02/19/2004 | US20040033987 Phosphorus compounds such as 1-palmitoyl-2-valproyl-glycero-3-phosphatidylcholine, used for prohylaxis of nervous system disorders such as epilepsy, migraine, bipolar disorders and pain |